Good news, that is:
__________________________________________________ ______________________________

Biogen, Elan Drug Effective in Crohn's
Tuesday October 24, 9:12 am ET
Biogen Idec and Elan Present Data Showing Effectiveness of Tysabri in Crohn's Disease


NEW YORK (AP) -- Biogen Idec and Elan Corp. said Tuesday data from a long term study of their multiple sclerosis drug Tysabri maintained remission rates in Crohn's disease patients treated over a two-year period.

The study involved 90 patients and showed 86 percent were still in remission after two years of continuous treatment. Also, a subpopulation of 22 patients who had previously taken infliximab therapy showed an 82 percent remission rate after two years.